We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLCO icon
226
Bausch + Lomb
BLCO
$5.99B
– –
-600
Closed -$11.6K
BMRN icon
227
BioMarin Pharmaceuticals
BMRN
$12.4B
– –
-1,200
Closed -$80.4K
BNTX icon
228
BioNTech
BNTX
$23.5B
– –
-10,000
Closed -$1.19M
BPMC
229
DELISTED
Blueprint Medicines
BPMC
– –
-5,100
Closed -$472K
BSX icon
230
Boston Scientific
BSX
$71.5B
– –
-2,500
Closed -$210K
CELC icon
231
Celcuity
CELC
$4.52B
– –
-3,000
Closed -$44.7K
CGEM icon
232
Cullinan Oncology
CGEM
$1.14B
– –
-54,358
Closed -$910K
CLDX icon
233
Celldex Therapeutics
CLDX
$3.28B
– –
-5,000
Closed -$170K
CRBP icon
234
Corbus Pharmaceuticals
CRBP
$190M
– –
-4,000
Closed -$82.5K
CVS icon
235
CVS Health
CVS
$122B
– –
-1,000
Closed -$62.9K
DYN icon
236
Dyne Therapeutics
DYN
$4.9B
– –
-400
Closed -$14.4K
ENGN icon
237
enGene Therapeutics
ENGN
$121M
– –
-1,970
Closed -$13K
EQ icon
238
Equillium
EQ
$133M
– –
-7,318
Closed -$6.09K
ESTA icon
239
Establishment Labs
ESTA
$2.28B
– –
-2,000
Closed -$86.5K
EWTX icon
240
Edgewise Therapeutics
EWTX
$4.73B
– –
-18,178
Closed -$485K
EYPT icon
241
EyePoint Inc
EYPT
$1.2B
– –
-2,000
Closed -$16K
FBRX icon
242
Forte Biosciences
FBRX
$1.57B
– –
-6,000
Closed -$33.5K
FDMT icon
243
4D Molecular Therapeutics
FDMT
$562M
– –
-6,000
Closed -$64.9K
KYNB
244
Kyntra Bio
KYNB
$29.4M
– –
-4,827
Closed -$48.2K
FULC icon
245
CALL
Fulcrum Therapeutics
FULC
$297M
– –
-15,000
Closed -$53.5K
GALT icon
246
PUT
Galectin Therapeutics
GALT
$348M
– –
-55,300
Closed -$152K
GLRE icon
247
Greenlight Captial
GLRE
$506M
– –
-4,385
Closed -$59.9K
ICHR icon
248
Ichor Holdings
ICHR
$2.56B
– –
-108
Closed -$3.44K
IDYA icon
249
IDEAYA Biosciences
IDYA
$3.56B
– –
-1,000
Closed -$31.7K
IMA
250
ImageneBio Inc
IMA
$64.6M
– –
-3,720
Closed -$77.2K
8 9
10
11 12

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.